China Oncology Information Systems Market Size & Outlook
China oncology information systems market, 2018-2030 (US$M)
Related Markets
China oncology information systems market highlights
- The China oncology information systems market generated a revenue of USD 100.5 million in 2022 and is expected to reach USD 199.1 million by 2030.
- The China market is expected to grow at a CAGR of 8.9% from 2023 to 2030.
- In terms of segment, software was the largest revenue generating product and services in 2022.
- Software is the most lucrative product and services segment registering the fastest growth during the forecast period.
Oncology information systems market data book summary
| Market revenue in 2022 | USD 100.5 million |
| Market revenue in 2030 | USD 199.1 million |
| Growth rate | 8.9% (CAGR from 2022 to 2030) |
| Largest segment | Software |
| Fastest growing segment | Software |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Software, Professional Services |
| Key market players worldwide | Elekta AB ADR, Accuray Inc, Siemens Healthineers AG ADR, RaySearch Laboratories AB Class B, Oracle Corp, Koninklijke Philips NV, ViewRay, Hochtief AG, McKesson Corp, BrainLAB, Prowess, Polaris Industries |
Other key industry trends
- In terms of revenue, China accounted for 3.9% of the global oncology information systems market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan oncology information systems market is projected to lead the regional market in terms of revenue in 2030.
- Japan is the fastest growing regional market in Asia Pacific and is projected to reach USD 229.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oncology Information Systems Market Scope
Oncology Information Systems Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China oncology information systems market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology information systems market will help companies and investors design strategic landscapes.
Software was the largest segment with a revenue share of 74.03% in 2022. Horizon Databook has segmented the China oncology information systems market based on software, professional services covering the revenue growth of each sub-segment from 2018 to 2030.
China's OIS market is anticipated to witness a significant growth rate of 8.9% over the forecast period, which can be attributed to the increasing prevalence of cancer and rising R&D in oncology. According to Globocan 2020, from the Global Cancer Observatory, over 4.5 million new cancer cases were diagnosed, and more than 3.0 million people died in China due to cancer.
In addition, every minute, six people are diagnosed with cancer. Moreover, major players are collaborating with Chinese hospitals, which, in turn, has increased the demand for OIS in this country.
For instance, Varian Medical Systems signed an agreement with Shandong Cancer Hospital in China for the installation of two of its software ARIA oncology information management system and Eclipse treatment planning software by the third quarter of 2019.
Reasons to subscribe to China oncology information systems market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China oncology information systems market databook
-
Our clientele includes a mix of oncology information systems market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China oncology information systems market , including forecasts for subscribers. This country databook contains high-level insights into China oncology information systems market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China oncology information systems market size, by product and services, 2018-2030 (US$M)
China Oncology Information Systems Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
